ArticleTranslational oncology2026
Targeting galactose metabolic reprogramming overcomes immunotherapy resistance in KRAS-mutant lung adenocarcinoma: Integrative multi-omics and machine learning approaches.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKRAS-mutant lung adenocarcinoma (LUAD) is associated with aggressive phenotypes and therapy resistance, which highlights an urgent need to identify reliable biomarkers and therapeutic targets. This study aims to investigate the role of galactose metabolism (GM) reprogramming in shaping the tumor microenvironment (TME) and driving immunotherapy resistance in KRAS-mutant LUAD.
methodsBulk-tissue transcriptomics data were collected from public cohorts such as Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). Single-cell RNA-sequencing (scRNA-seq) data, mutational profiles, and advanced bioinformatic approaches were integrated to analyze the correlation between mutation status and metabolic heterogeneity in LUAD. Analytical methods included dimensionality reduction, differential expression, intercellular communication, trajectory inference, gene co-expression network analysis, molecular subtyping, and machine learning-based prognostic modeling. Animal experiment and flow cytometry were performed to validate KDM5A inhibitor (CPI-455) can sensitize KRAS-mutant LUAD cells to immunotherapy.
resultsSingle-cell analysis revealed reduced immune infiltration and upregulated GM in KRAS-mutant epithelial cells. Two GM-based molecular subtypes with distinct mutational profiles and immune patterns were identified. A prognostic model integrating GM-related genes demonstrated superior predictive performance. KDM5A was identified as a key predictor of ICB resistance. Targeting KDM5A can enhance the sensitivity to immunotherapy in KRAS-mutant LUAD.
conclusionOur findings highlight the therapeutic potential of targeting galactose metabolism-related hub genes to sensitize KRAS-mutant LUAD to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.